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Objective:Morquio A syndrome (mucopolysaccharidosis IVA;MPS IVA) is an autosomal recessive lysosomal
storagedisorder caused by deﬁcientN-acetylgalactosamine-6-sulphatase (GALNS) activity. Early and accurate di-
agnosis of this condition is critical for improved patient outcomes, particularly as enzyme replacement therapy
has recently become available. An LC–MS/MS assay utilising keratan sulphate (KS) disaccharides derived from
keratanase-II digestion provides a sensitive and speciﬁc means for quantitation of urinary KS, a screening
biomarker for Morquio A (Oguma et al., 2007; Martell et al., 2011). To ensure a reliable supply of keratanase-II,
we sought to produce a Bacillus circulans-derived enzyme via a recombinant approach in Escherichia coli.
Design and methods: Bioinformatics analysis of the B. circulans keratanase-II enzyme identiﬁed likely
dispensable C-terminal domains amenable to enhancement via protein engineering. A truncated form of the
enzyme was designed to remove the domains predicted to be unnecessary for catalytic activity and detrimental
to recombinant expression in E. coli.Results: C-terminally truncated, recombinant B. circulans keratanase-II was puriﬁed to N98% homogeneity
and extensively characterised, demonstrating desired activity, speciﬁcity and utility in LC–MS-based quantitation
of urinary KS fromMorquio A and control samples, and is functionally indistinguishable from full-length, native
B. circulans-derived keratanase-II.
Conclusions: This novel, recombinant keratanase-II meets all performance requirements and can be
produced in a rapid and reproducible manner. We speculate that other related bacterial enzymes of biomedical
or industrial interest may be amenable to similar engineered enhancements.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The glycosaminoglycan keratan sulphate (KS) consists of β-(1→ 3)
repeats of a galactosyl β-(1 → 4)-N-acetylglucosamine disaccharide
unit [1]. KS has been identiﬁed as a key mediator in a multitude of bio-
logical processes, ranging from embryonic development [2], axonal
guidance, metastatic tumour invasion [3] and modulation of immune
recognition via both the innate [4] and adaptive systems [5]. In normal
metabolism, KS is catabolised in the lysosome into its component sugars
and sulphate which are then recycled or excreted. Deﬁcient activity ofard).
unnels Wood Road, Stevenage,
iety of Clinical Chemists. PublisN-acetylgalactosamine-6-sulphatase (GALNS; EC 3.1.6.4), an enzyme
that catabolises KS and chondroitin-6-sulphate, causes Morquio A syn-
drome (mucopolysaccharidosis IVA; MPS IVA), a disorder in which
accumulated KS leads to progressive tissue and organ dysfunction [6,
7]. Management of the disorder until recently has been limited to sup-
portive and symptom-based care; however, enzyme replacement ther-
apy (ERT) with elosulfase alfa is now a treatment option [8]. Urinary KS
has been proposed as a screening biomarker for Morquio A syndrome,
and a validated liquid chromatography–tandem mass spectrometry
(LC–MS/MS) assay for KS quantitation in urine has been described [9].
A key component of this assay is the use of a keratanase enzyme to di-
gest urinary KS into disaccharides for subsequent quantitation.
KS disaccharides are generated by use of Bacillus circulans
keratanase-II (endo-β-N-acetylglucosaminidase), which cleaves
N-acetylglucosamine linkages within the KS chain to yieldhed by Elsevier Inc. This is an open access article under the CC BY license
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tetrasaccharides consisting of two repeats of this unit linked via
a 1–3 bond (Gal(1–4)GlcNAc(1–3)Gal(1–4)GlcNAc). Unlike other
keratanases, the enzyme from Bacillus sp. is not inhibited by the
presence of adjacent fucose on N-acetylglucosamines [10], making
it attractive for the analysis of this substrate. The keratanase-II
gene from B. circulans is 5808 bp long and encodes a 1936 amino
acid protein devoid of cysteine residues [11]. The N-terminal 34
amino acids of the protein likely represent a signal peptide (SignalP
4.0; [12]) downstream from which is a large domain with little overall
homology to other known proteins, assumed to be the catalytic domain
(Fig. 1). Homology with other proteins is highest at the C-terminus
which contains three repeats of a bacterial surface layer homology
(SLH) domain. SLH domains [13] are found in many bacterial enzymes
that play a role in the degradation of complex polysaccharides. Each in-
dividual SLH domain is approximately 60 residues long and mediates
binding to non-classical, pyruvylated secondary cell wall polymer
(SCWP) components of both Gram positive and Gram negative bacterial
cell walls [14].
To facilitate the expression and characterisation of the B. circulans
keratanase-II in Escherichia coli, we conducted a detailed bioinformatics
analysis of the protein resulting in the expression of a truncated version
of the enzyme. Unlike a full-length recombinant version, the truncated
form was fully soluble and maintained both the activity and speciﬁcity
of the enzyme puriﬁed from its native source. Furthermore, we demon-
strate that it facilitates digestion and subsequent quantitation of KS in
urine fromMorquio A-affected andunaffected individuals in amanner in-
distinguishable from the full-length, native B. circulans-derived enzyme.
2. Materials and methods
2.1. Molecular cloning
The keratanase-II gene (NCBI AY188989; UniProt Q7X0Z0) was
synthesised by Life Technologies and subcloned into the BamHI
and XhoI sites of pET22b (modiﬁed to remove the pelB leader),
resulting in the expression construct pBM001 which placed a His6
tag at the extreme C-terminus of the enzyme. The truncated con-
struct described (pBM002) was generated by amplifying the region
of interest using CloneAmp high-ﬁdelity polymerase (Clontech) and
cloning into pET22b using Infusion cloning (Clontech). Recombi-
nant clones were identiﬁed and plasmid DNA puriﬁed and se-
quenced. For expression, positive clones were transformed into
the E. coli DE3 lysogen BL21(DE3)pLysS [15].
2.2. Recombinant protein expression and puriﬁcation
BL21(DE3)pLysS E. coli harbouring the plasmid of interest were
grown with shaking in LB medium containing 100 μg/mL ampicillin atFig. 1. Conserved domains within B. circulans keratanase-II (A) native, full-length enzyme and
binding domain (CBM_4_9), residues 81–192, D: domain of unknown function (DUF), residu
complexity ‘linker’ region, residues 1498–1571; S: SLH domains, residues 1750–1936. The puta37 °C until an OD600 of 0.6 to 0.8. IPTG (1 mM ﬁnal concentration) was
added and growth continued for 3 h. Cellswere harvested by centrifuga-
tion, re-suspended in 2–10mL PBS/1 MNaCl supplemented with 10 μg/
mL lysozyme (w/v) and frozen at−80 °C. After thawing, cells were son-
icated and the soluble fraction was collected by a clarifying spin at
15,000 rpm for 60 min. Target protein was puriﬁed using pre-packed
columns (GE Healthcare) on an Akta ‘Pure’ instrument (GE Healthcare).
The truncated enzyme was puriﬁed from the soluble fraction of a
500mL culture by application to a 5mLHisTrap-HP column and elution
with a linear gradient of 0−250 mL imidazole. Peak fractions were
pooled and buffer exchanged into PBS/3 M NaCl, before applying to a
5 mL phenyl sepharose hydrophobic interaction (HIC) column. 2 mL
fractions were collected from the gradient and characterised by SDS-
PAGE. The ﬁnal product was buffer exchanged into PBS/20% glycerol
and stored at−80 °C until required.
2.3. SDS-PAGE and immunoblotting
Samples were prepared and analysed on SDS-PAGE using precast
‘Bolt’ gels and associated buffers (Life Technologies), running in MES
buffer conditions, according to the manufacturer's recommendations.
For immunoblotting, gels were equilibrated in 1× NuPAGE transfer
buffer prior to transfer to nitrocellulose membrane for 60 min at 25 V
constant voltage. Proteins were detected with a Sigma anti-His tag
monoclonal antibody (Cat #H1069) at 1:2500 using buffers and detec-
tion reagents from the Life Technologies ‘Western Breeze’ chromogenic
system.
2.4. Keratanase activity assay
Keratanase activitywas assayed using a variation of the neocuproine
assay described by Bureau andMacGregor [16]. Brieﬂy, a standard curve
of a representative reducing sugar (N-acetyl glucosamine; GlcNAc) was
generated by adding 60 μL 0–100 μg/mL GlcNAc to a mixture of 100 μL
neocuproine (made with 0.151 g in 100 mL water) and 100 μL ‘reagent
A’ (made with 4.00 g Na2CO3, 1.63 g glycine and 47 mg CuSO4·5H2O in
100mLwater) and heating at 100 °C for 12min, followed by cooling on
ice. 100 μL of the above sample was diluted with 100 μL water, mixed
well and the absorbance at 405 nm (A405) read in a SpectraMax plate
reader. The data were plotted as a scatter of A405 versus concentration
of reducing sugar (GlcNAc) in μg/mL using Microsoft Excel. A linear ﬁt
was calculated using the software and the equation used for interpola-
tion of the sample readings. One unit was deﬁned as the amount of en-
zyme that released 1 μmol of reducing sugars per minute under the
assay conditions.
To assay the enzyme, 10 μL of the puriﬁed enzyme was added to
10 μL of KS (GlycoSyn, New Zealand), from bovine cornea, 2 mg/mL in
assay buffer (100 mM sodium acetate, pH 6.0), in a total volume of
60 μL assay buffer. Samples were placed at 37 °C for 30 min followed(B) C-terminally truncated enzyme. P: leader peptide (residues 1–34), C: carbohydrate
es 227–294; U: UgpB domain (periplasmic sugar transport), residues 1071–1421; L: low
tive catalytic domain is identiﬁed by the black arrow.
Fig. 2. Analysis of recombinant B. circulans keratanase-II expression from induced whole
cell-lysates; (A) stained SDS-PAGE and (B) immunoblot with anti-His. Lane 1: Novex
‘Sharp’ molecular weight markers (Life Technologies: sizes indicated in kDa), lane 2:
uninduced cell lysate, lane 3: ‘full-length’ recombinant keratanase-II (residues 35–1936,
predicted m.w. 210,682 Da), lane 4: truncated, recombinant keratanase-II (residues 35–
1502, predicted m.w. 165,156 Da). The bands corresponding to the full-length recombi-
nant keratanase-II-His6 and the truncated keratanase-II-His6 are identiﬁed by the open
and ﬁlled triangles, respectively.
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added to a mixture of 100 μL neocuproine and 100 μL ‘reagent A’ as de-
scribed above. 100 μL of the sample was diluted with 100 μL water and
the A405 determined. A range of enzyme concentrations was tested to
identify values within the linear range of the assay and the unit deﬁni-
tion at the relevant concentration calculated by determining the inter-
cept on the standard curve at this concentration.
2.5. β-D-Galactosidase assay
The levels of contaminating β-D-galactosidase activitywere assessed
by measuring the hydrolysis of p-nitrophenyl β-galactopyranoside
(PNPG) to yield a coloured reaction product at 405 nm, essentially as de-
scribed by Torpenholt et al. [17]. A standard curve was generated using
dilutions of E. coliβ-D-galactosidase (667U/mL, Sigma) at a range from0
to 1000 mU/mL. The enzyme dilutions were added to 2 mM PNPG and
the A405 monitored at 10 s intervals to yield Vmax values for each en-
zyme concentration. Vmax was then plotted against enzyme concentra-
tion (in mU/mL). Dilutions of the keratanase-II enzyme preparations
were tested at different concentrations up to 1 mg/mL in the same
assay and the intercepts on the curve were calculated. Readings that
were below the lowest point on the standard curve (5 mU/mL) were
deemed to be below the lower limit of quantitation (LLoQ) of the assay.
2.6. Quantitative LC–MS/MS analysis of KS in urine
Blinded urine samples consented for research use were obtained
from individuals with Morquio A syndrome [8] and from unaffected,
healthy individuals (Bioreclamation, NY, USA). A total of 24 urine sam-
ples from12Morquio A-affected individuals (age range 5–41 years) and
10 urine samples from 10 unaffected, healthy individuals (age range 7–
25 years) were digested with keratanase-II and analysed using a
modiﬁed version of a validated LC–MS/MS method [9]. This method,
based on a previously described assay [18], utilises mono-[Galβ(1–4)
GlcNAc(6S)] and disulphated [Gal(6S)β(1–4)GlcNAc(6S)] KS disaccha-
rides derived from keratanase-II digestion for targeted KS quantitation.
Each urine sample underwent digestion using (i) full-length, native
B. circulans keratanase-II (Seikagaku Corporation, Japan) and (ii) the
novel, truncated, recombinant B. circulans keratanase-II. Brieﬂy, 90 μL
of each urine sample was transferred to a 96-well plate and diluted
with 10 μL of water. 100 μL of 0.1 M ammonium acetate buffer (pH 7)
and 10 μL of 0.02 U/mL keratanase-II (20 ng) were added and the solu-
tion was mixed. After digestion at 40 ± 2 °C for 2–4 h, 100 μL each of
heavy-isotope-labelled internal standards Galβ(1-4)GlcNAc(6S),13C6,
and Gal(6S)β(1-4)GlcNAc(6S),13C6 (GlycoSyn) were added. The solu-
tion was transferred to a ﬁlter plate and centrifuged at 4000 rpm for
1 h. The generated KS disaccharides were separated by high perfor-
mance liquid chromatography (HPLC) and measured by MS/MS using
multiple reaction monitoring (MRM) in negative ion mode. LC–MS/
MS analysis was performed using a Shimadzu binary solvent delivery
unit LC-20ADwith SIL20AC autoinjector, a Thermo Scientiﬁc Hypercarb
5 μm column (50 × 2.1 mm), and an AB Sciex Triple Quad 5500 mass
spectrometer. The mobile phase consisted of a mixture of buffer A:
25 mM ammonium acetate and 6 mM tributyl amine (TBA), pH 7, and
buffer B: 25mM ammonium acetate and 6 mM TBA, pH 7 in 80% aceto-
nitrile (MeCN). Gradient conditions were programmed as follows: the
initial buffer B composition of 0% was linearly increased to 20% over
0.5 min, then to 30% over 1 min and maintained at 30% for 0.7 min,
then modiﬁed to 100% over 0.01 min and maintained for 0.19 min,
then decreased to 0% over 0.01 min and ﬁnally maintained at 0% for
3.09 min. Flow rate was 0.4 mL/min. The MS ion source temperature
was set at 600 °C and the data were collected over 4 min. Analyst v1.6
software (AB Sciex) was used for data acquisition and handling.
All LC–MS/MS analyses were performed in triplicate. Urine KS was
reported as the sum of the two disaccharides normalised to creatinine
excretion (μg/mg creatinine). Spectrophotometric determination ofcreatinine, based on the Jaffe procedure, was performed by Quest
Diagnostics.
3. Results
3.1. Cloning and expression of full-length keratanase-II in E. coli
The entire ORF for B. circulans keratanase-II was used to generate a
pET22b based expression construct which placed the keratanase-II
gene downstreamof the T7 promoter. Analysis of the cell pellet from in-
duced E. coli bearing this plasmid demonstrated expression of a signiﬁ-
cant amount of protein of the expected size (Fig. 2; panel A, lane 3),with
a smaller induced band also visible. Lysis by freeze/thaw and sonication
to resolve soluble and insoluble protein fractions indicated distribution
of the overexpressed protein between the soluble and insoluble frac-
tions. Subsequent attempts to purify the protein from either soluble or
insoluble fractions using HisTag afﬁnity capture were unsuccessful,
yielding no detectable puriﬁed material (not shown), consistent with
the inability to detect the protein by anti-His tag immunoblot (Fig. 2;
panel B, lane 3).
3.2. Bioinformatics analysis and design of truncated forms of keratanase-II
In order to determinewhether therewere aspects of the keratanase-
II sequence that could be engineered to enhance expression and recov-
ery, the sequence of the protein was analysed using the NCBI BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and DELTA_BLAST servers and
associated tools.
A number of conserved structural domains were identiﬁed (Fig. 1),
including a long unstructured ‘linker’ region (L) approximately 70
amino acids longwith a highly repetitive sequence (GE(E/Q)P) followed
by a series of small amino acids (G, A, N, Q, S, D, E). Based on these ob-
servations it was hypothesised that the quaternary structure of the pro-
tein consisted of an N-terminal catalytic domain and a C-terminal
anchoring domain, joined by the extended linker. This prompted the re-
moval of the C-terminal SLH domains and the linker region, resulting in
the relocation of the His-tag to the C-terminus of the putative catalytic
domain.
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generated (pBM002). In this construct the keratanase was truncated at
amino acid 1502, after which was encoded a C-terminal His6 tag. Upon
induction, overexpressed protein was seen clearly for this truncated
version (Fig. 2; panel A, lane 4)with the band size corresponding closely
to the calculated molecular mass of the protein (165,156 Da). The ex-
pression level observed for the truncated form of the protein (indicated
by the black arrow; lane 4) was substantially greater than for the full-
length version (white arrow, lane 3) and anti His-tag immunoblots of
the extracts revealed that the antibody detected only the truncated ver-
sion, despite both forms encoding the His6 tag (Fig. 2; panel B, lanes 3
and 4).
3.3. Puriﬁcation and analysis of truncated keratanase-II
The truncated keratanase-II was expressed on a larger (500 mL)
scale for further analysis. After lysis the protein was puriﬁed from the
soluble fraction using a 2-step process (as described in ‘Materials
and methods’) resulting in material that was shown to be N98%
pure by both densitometry (Fig. 3) and analytical SEC (Superdex
200 10/300GL; Fig. 3). Based on initial expression levels of approxi-
mately 40 mg/L, ﬁnal recovery was calculated to be greater than
60%. The protein was formulated at 2.0 mg/mL in PBS/20% glycerol
and stored at−80 °C.
3.4. Activity and speciﬁcity determination
Batches of truncated enzymewere assayed for keratanase activity as
described inMaterials andmethods (Supplementary data, Table S1). KS
(20 μg) was used as the substrate and 1 μg/mL of the truncated enzyme
was compared with native keratanase-II puriﬁed from B. circulans
(Seikagaku Corporation). While the full-length, native B. circulans-
derived enzymewas consistently observed to bemore active than spec-
iﬁed by the manufacturer (as measured by units of activity in our
neocuproine assay), the speciﬁc activities of both enzymes were found
to be very similar and it was concluded that the catalytic activity of
the truncated enzyme was effectively comparable to that of the native
enzyme.
To conﬁrm that the recombinant, truncated enzyme had not relaxed
its substrate speciﬁcity compared with the native, full-length enzyme,
the following assays were performed to assess speciﬁcity for a
range of related substrates using the following control enzymes:
chondroitinase (Seikagaku), heparinase, heparitinase (both from Ibex
Pharma), neuraminidase, hyaluronidase, β-N-acetylglucosaminidase
and β-D-galactosidase (all from Sigma). No activity above the LLoQFig. 3. Puriﬁcation of truncated, recombinant, B. circulans keratanase II. (A) SDS PAGE of puriﬁe
(5 μg). (B) Analytical SEC of puriﬁed, truncated enzyme.was detected in any of the assays (data not shown) although with-
out the HIC puriﬁcation, contamination from residual E. coli β-D-
galactosidase could be detected (Supplementary data, Table S1).
3.5. Quantitative LC–MS/MS analysis of urine KS levels
The performance of the recombinant, truncated and full-length, na-
tive keratanase-II enzymes was compared in the LC–MS/MS determina-
tion of KS levels in urine from 12Morquio A-affected and 10 unaffected,
healthy individuals (controls). Digestion efﬁciencies were comparable
for both enzymes, ranging from 30 to 60% (depending on experimental
conditions) as measured by % w/w sum of disaccharides to KS. Repre-
sentative ion chromatograms are shown in Fig. 4. Baseline separation
of the mono- and disulphated disaccharides was achieved in less than
3 min. As shown in Fig. 5, the quantitative results obtained using trun-
cated keratanase-II are in excellent agreement with those obtained
using the full-length, native enzyme. Mean urine KS levels for Morquio
A-affected individuals were in the range 1.28–37.37 μg/mg creatinine as
determined following digestion by full-length keratanase-II, and 1.24–
35.67 μg/mg creatinine as determined following digestion by the trun-
cated enzyme. As expected, mean urine KS levels were comparatively
lower in unaffected individuals, ranging from 0.23 to 1.48 μg/mg creat-
inine as determined following digestion by the full-length, native en-
zyme, and 0.28–1.57 μg/mg creatinine as determined following
digestion with recombinant, truncated enzyme. Twenty-two of the 24
Morquio A samples showed elevatedmean KS levels relative to the nor-
mal range across all ages that were approximately 5- to 40-fold higher
than those of age-matched control samples. The twoMorquio A samples
with mean KS levels that fell within the normal range across all ages
(samples 21 and 22) were both obtained from an older patient aged
33 years; nonetheless, these KS levels were approximately 5 times
higher compared to age-matched controls. For both patient and con-
trol samples, the lowest urine KS levels were associated with indi-
viduals N20 years of age.
This LC–MS/MS method is highly reproducible, with CVs of three
replicate analyses ranging from 0.51 to 10.03%. To maintain optimal
enzyme stability, aliquots of the enzyme were stored at −20 °C to
−80 °C and were rapidly thawed prior to use in the assay.
4. Discussion
Screening for KS elevation, as observed in disorders such asMorquio
A, through quantitation by LC–MS/MS requires a keratanase enzyme
that can digest urinary KS into disaccharides. Keratanase-II from
B. circulans was identiﬁed as an ideal candidate enzyme. To overcomed, truncated enzyme. M: Novex ‘Sharp’ pre-stained standards; S: truncated keratanase-II
Fig. 4. Representative LC–MS/MS chromatograms of KS disaccharides with isotopic internal standards in urine from a Morquio A individual following (A) digestion by full-length native
B. circulans keratanase-II and (B) digestion by recombinant, truncated B. circulans keratanase-II. The use of heavy-isotope-labelled internal standards ensures robust quantita-
tion and is a key distinguishing feature of this LC–MS/MS assay. MRM transitions:m/z 462 to 361 [Galβ1–4GlcNAc(6S)];m/z 468 to 367 [Galβ(1–4)GlcNAc(6S),13C6];m/z 542 to
462 [Gal(6S)β1–4GlcNAc(6S)]; m/z 548 to 468 [Gal(6S)β(1–4)GlcNAc(6S),13C6]. The very small peaks at 2.70 min come from in-source fragmentation of Galβ1–4GlcNAc(6S)
and Galβ(1–4)GlcNAc(6S),13C6.
800 M. Steward et al. / Clinical Biochemistry 48 (2015) 796–802the limitations of extracting the keratanase-II enzyme from its native
host, we employed a recombinant route to secure a reliable, robust
and scalable source of enzyme for diagnostic use. However, full-length
keratanase-II expressed in E. coli behaved unpredictably and could not
be puriﬁed via the C-terminal His6 afﬁnity tag. Sequencing of the clones
conﬁrmed that the His6 tag was present and there were no frameshifts
or stop codons (not shown). Therefore, we reasoned that a C-terminal
region of this large and relatively poorly characterised protein may be
responsible for adversely impacting the expression of intact and active
enzyme in E. coli.
The amino acid sequence of the protein was compared against the
entire non-redundant protein sequence database, identifying ap-
proximately 250 related proteins. In almost all cases the homology
was located entirely within the C-terminal extreme of the protein
(Supplementary Fig. S1). Pfam [19] analysis identiﬁed three copies
of the bacterial surface layer homology (SLH) domain within this
region of the protein. SLH domains are particularly prevalent in
Clostridium (Thermoanaerobacter), Paenibacillus and Bacillus species
and are frequently associated with enzymes that are involved in
the degradation of complex polysaccharides. It is known that SLH
domains are involved in the anchoring of extracellular enzymes
within the bacterial peptidoglycan [20,21], therefore the sequence
homology within this region is unsurprising given the relative lack
of variability within peptidoglycans from distantly related bacteria.
The structure of an SLH domain from B. anthracis surface array protein
(SAP) shows a trimeric structure with three ‘prongs’ [22] containing
positive charges thatmediate the interactionwith pyruvylated structures
in the secondary cell wall peptidoglycan (SCWP).
In addition to the characteristic SLH domains, our analysis of the
keratanase-II protein revealed a second, less well-characterised featureadjacent to the SLH domains: an extended stretch of highly repetitive
amino acids forming a ﬂexible, unstructured region rich in glutamate,
glutamine, glycine and proline residues (Supplementary Fig. S2). We
speculated that the function of this region was to act as a linker which,
in an extended form, could potentially span up to 300 Å. Such a linker
would potentially allow the catalytic domain to function at a distance
from the anchoring SLH domain, beyond the capsular polysaccharide
of the B. circulans cell wall, as illustrated schematically in Fig. 6. Based
on this premise, it was predicted that both the linker and the SLH
domains could be deleted without affecting the substrate speciﬁcity or
catalytic activity of the enzyme.
The prediction that the removal of the C-terminal domains
would result in improved properties was borne out by observations
that the truncated keratanase-II could be readily detected with an
anti-His6 antibody and puriﬁed on His-Tag afﬁnity columns, unlike
the full-length recombinant keratanase-II. The observation that de-
letion of the linker and SLH domains improved both the yield and
solubility of keratanase-II is at odds with the work of Yamagishi
and colleagues [11] who suggested that the SLH domains were nec-
essary for the solubility of the recombinant keratanase-II on the
basis of reduced yields of a ‘truncated’ version of keratanase-II.
Yamagishi et al. did not specify the point within their construct
that the truncation occurred and it may be that their truncated
form of keratanase-II retained or lost sequence that affected either
activity or biophysical behaviour. Consistent with the domain
attributions based on the sequence analysis, we observed that the
truncated form of keratanase-II showed equal activity to the com-
mercially sourced enzyme puriﬁed from B. circulans. In addition,
the enzyme maintained its natural speciﬁcity, demonstrating no
activity on a range of other glycosaminoglycans.
Fig. 5.Mean urine KS levels from (A) Morquio A-affected individuals (purple) and (B) healthy, unaffected individuals (blue) as determined by LC–MS/MS following digestion by full-
length, native B. circulans keratanase-II (darker bars) versus digestion by truncated, recombinant B. circulans keratanase-II (lighter bars). Error bars represent standard deviations.
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the native B. circulans-derived enzyme in the LC–MS/MS quantitation
of KS in 34 urine samples. We found that digestion using truncated
keratanase-II produced quantitative urinary KS data that were in close
agreement to data obtained using the native, full-length enzyme,
illustrating equivalence of activity. Furthermore, these data show thatFig. 6. Conceptual diagram illustrating proposed structure of the native, B. circulans
keratanase-II enzyme (A) and its relationship to the components of the bacterial cell
wall. The predicted nature of the truncated, recombinant B. circulans keratanase-II (B) is
shown for comparison.urinary KS levels are, in general, signiﬁcantly higher in individuals
with Morquio A syndrome than in unaffected individuals, thereby
conﬁrming the utility of the engineered enzyme.Whilewe demonstrate
that this LC–MS/MS method can be used to differentiate Morquio A
fromunaffected individuals, particularly at an early agewhen the differ-
ence in KS levels is greatest, our data corroborate ﬁndings from other
studies that indicate that urinary KS levels decrease with age [9,23]
and underscore the importance of using age-speciﬁc reference
ranges to avoid or reduce the potential for false negatives in older
individuals. As other disorders, including Morquio B, fucosidosis,
and the mucolipidoses, can elevate urinary KS [24], false positives
are also possible. Hence, while this LC–MS-based urinary KS assay
represents a sensitive, speciﬁc, rapid, convenient, and non-invasive
screening method for Morquio A syndrome, GALNS enzyme activity
testing is necessary for deﬁnitive diagnosis [25]. Although KS is also
measurable in plasma [9,18], the biological relevance is unclear as
plasma KS levels in Morquio A and unaffected individuals largely
overlap.
The extent to which the properties of the keratanase-II enzyme im-
proved after truncation of the linker and SLH domains has led us to con-
sider whether this might represent a generic approach for producing
enzymes of biomedical or industrial utility that are naturally found as
802 M. Steward et al. / Clinical Biochemistry 48 (2015) 796–802SLH-containing proteins. The majority of the related sequences identi-
ﬁed from BLAST searches are bacterial extracellular enzymes responsi-
ble for digesting carbohydrate substrates. These enzymes largely
conform to a similar domain topology, containing a linker region be-
tween the catalytic and the SLH domains. The capacity of bacteria to de-
grade complex carbohydrates makes enzymes of this type potentially
valuable for industrial or biomedical purposes.
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